Cellectis (NASDAQ:CLLS) Now Covered by StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued to investors on Monday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Barclays lowered their price target on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

Cellectis Price Performance

CLLS stock opened at $1.56 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. Cellectis has a 1 year low of $1.53 and a 1 year high of $3.55. The firm has a 50-day moving average of $1.86 and a 200 day moving average of $2.04. The company has a market cap of $86.71 million, a P/E ratio of -1.20 and a beta of 3.09.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The firm had revenue of $18.05 million during the quarter, compared to analysts’ expectations of $5.00 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. During the same period in the previous year, the company earned ($0.31) earnings per share. On average, sell-side analysts forecast that Cellectis will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Cellectis

A number of hedge funds have recently added to or reduced their stakes in CLLS. Principal Financial Group Inc. boosted its stake in Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Cellectis during the 2nd quarter valued at about $29,000. Long Focus Capital Management LLC grew its stake in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares during the period. Finally, First Affirmative Financial Network bought a new position in Cellectis during the third quarter valued at approximately $45,000. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.